迈帝法马

Medipharm is a Shanghai-based biotechnology company dedicated to the development of innovative drugs through targeted protein degradation (TPD) technology. The company leverages its proprietary PROTAC platform to target proteins that are traditionally considered undruggable or have developed resistance to standard inhibitors. Medipharm's research and development efforts are primarily concentrated in the fields of oncology and autoimmune diseases, with lead programs targeting the androgen receptor and Bruton's tyrosine kinase. By utilizing the ubiquitin-proteasome system to degrade specific pathogenic proteins, the company aims to create more potent and durable therapeutic options. Medipharm is led by a team of experienced drug discovery professionals and has secured significant backing from prominent venture capital firms like Qiming Venture Partners.